Downstream AAV Purification Using Affinity and Ion-Exchange Chromatography
AAV PURIFICATION: AFFINITY AND ION-EXCHANGE CHROMATOGRAPHY
Downstream AAV Purification Using Affinity and Ion-Exchange Chromatography
CELL & GENE | RNA | BIOLOGICS
Proven Intelligence in AAV Process Development.
Executive Summary
The purification of recombinant AAV vectors is a defining step in CMC process development, directly impacting the safety and efficacy profile of a next-generation therapeutic. The primary objective is the efficient removal of process-related impurities: including host cell proteins, DNA, and empty capsids from the final vector preparation. Franklin Biolabs employs a data-driven strategy to select and optimize downstream purification trains, primarily utilizing affinity and ion-exchange chromatography, tailored to specific AAV serotypes and the intended clinical application. This approach ensures the delivery of highly pure, potent vectors suitable for IND-enabling toxicology studies and subsequent clinical evaluation, aligning with harmonized ICH, FDA, and EMA guidelines for multi-jurisdictional submissions.
Frequently Asked Questions
Q: How does the choice of AAV purification method impact readiness for IMPD or IND submissions?
The purification method is fundamental to the CMC section of any regulatory submission. A well-characterized process using affinity or ion-exchange chromatography provides regulators with confidence in product consistency, purity, and safety. It demonstrates control over the removal of empty capsids and process residuals, which is a key point of evaluation for agencies like Swissmedic, the EMA, and the FDA.
Q: Can a single purification platform work for all AAV serotypes, including engineered capsids?
A one-size-fits-all platform is not optimal. While certain affinity resins show broad applicability, their binding efficiency can vary significantly between serotypes like AAV8 and AAV9, or with novel engineered capsids. Ion-exchange chromatography requires even more specific process development. A tailored strategy is necessary to maximize yield and purity for each unique vector.
Q: What is the primary challenge in separating empty from full AAV capsids during downstream processing?
The primary challenge is their structural similarity. Empty and full capsids share the same protein shell and have very similar sizes and isoelectric points. Ion-exchange chromatography is the most effective technique for this separation, as it can resolve the subtle surface charge differences between DNA-filled (full) and empty capsids.
Tailoring Downstream AAV Purification Strategies
Achieving a high percentage of full, functional AAV capsids is a primary objective of downstream process development. The presence of empty capsids can increase the total viral particle dose required for therapeutic effect, potentially saturating cellular uptake mechanisms and contributing to unwanted immunogenicity without providing any therapeutic benefit. The selection of a purification train represents a defining decision point in any AAV program.
Our scientific team, whose work contributed to a 100% successful IND rate since 2019 prior to the formal launch of Franklin Biolabs in 2024, has deep experience in developing these customized processes. This continuity of expertise ensures that programs are built on a foundation of proven success.
Affinity Chromatography: Specificity and Speed
Affinity chromatography often serves as the primary capture step in AAV purification. It leverages resins with ligands that have a high binding affinity for the AAV capsid surface.
High Specificity: This method can achieve high levels of purity in a single step by selectively binding the AAV particles and allowing most host cell contaminants to flow through.
Process Efficiency: It simplifies the overall purification workflow, potentially reducing the number of required downstream steps and accelerating process timelines.
Serotype Considerations: The development of pan-serotype affinity ligands has broadened applicability, though optimization is still required for novel or engineered capsids to ensure efficient capture and elution without compromising vector integrity.
Ion-Exchange Chromatography: Resolution and Purity
Ion-exchange chromatography (IEX) separates molecules based on their net surface charge. For AAV purification, it is an exceptionally powerful tool for resolving full capsids from empty ones, a step often necessary to meet the stringent purity requirements for clinical use. The successful delivery of complex constructs, such as those required for segmental trans-splicing to express large proteins like CFTR (PMID: 19257851), depends on this high degree of purification to isolate the functional vector.
This level of precision is also vital when developing vectors for sensitive applications, like the intranasal delivery of an ACE2 decoy to prevent respiratory virus infection (PMID: 34265018), where minimizing immunogenic contaminants is a primary concern.
The transition from academic discovery to a viable preclinical candidate requires this level of manufacturing rigor. As one biotech partner noted, “Wonderful services. Excellent team to work with. Vast knowledge in all aspects of vector production and analytics.”
For a deeper analysis of vector design and scalability, our recent webinar provides insights into initiating successful AAV programs [FBL-VID-03]. Franklin Biolabs combines these advanced purification techniques within our >100,000 sq ft facility to support programs aiming for an 18-24 month IND timeline.
